A systematic review of flurbiprofen 8.75 mg dose and risk of adverse events (excluding haemorrhagic) resulting from drug-drug interactions.

Flurbiprofen 8.75 mg lozenges and oromucosal sprays are used for symptomatic relief of sore throat in patients aged 12 years and over. The documented adverse events of flurbiprofen use include those related to its pharmacological actions, namely, increased risk of haemorrhagic events, however other adverse events (such as nephrotoxicity and cardiac failure) have been known to occur.

Griffiths-like behavior and magnetocaloric properties of rare-earth silicide TbCoSi.

Novel rare-earth silicide, TbCoSicompound, crystallizes in LuCoGastructure, a distorted substitution variant of thestructure. The compound exhibits a complex magnetic state, with a ferromagnetic transition at 58 K, followed by successive antiferromagnetic transitions at 24 K and 8 K, respectively. Isothermal and magnetic hysteresis studies indicate the prominence of competing antiferro and ferromagnetic interactions in the compound.